Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia.
Inevitably, the greater availability of more costly antipsychotic medications has resulted in attempts to regulate the use of these agents. Early objections over the cost of treatment with clozapine or risperidone have in part been mollified by preliminary statistics on the cost effectiveness of these agents. However, this issue is complex and requires careful consideration of pharmacoeconomic principles in the development and clinical distribution of novel antipsychotics. Future cost-effectiveness studies need to consider a balance of public and private perspectives. These studies should be conducted in several settings, preferably also within the context of broader, multimodal treatment intervention strategies.
Zito
J M
JM
School of Pharmacy, University of Maryland, Baltimore, USA.
D014150:Antipsychotic Agents / Q000191:economics* / Q000592:standards; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D003024:Clozapine / Q000191:economics / Q000592:standards; D003362:Cost-Benefit Analysis; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000191:economics / Q000592:standards; D018967:Risperidone / Q000191:economics / Q000592:standards; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine